HTx is a EU-funded project (H2020) aiming to set the standard to the next generation of health technology assessment (HTA) to support patient-centric, socially oriented and real-time decision making for health technologies throughout Europe—the HTx project.

The oncology case study led by the EORTC focuses on the clinical efficacy and real-world effectiveness of proton therapy among patients with head and neck cancer. As a first step, subgroups of patients are identified who are most likely to benefit from proton therapy in terms of minimizing radiation-related toxicities. Thereafter the researchers look into a bigger picture at the impact on population level to see if and how proton therapy saves lifes and costs in contrast to the conventional photon therapy for the society, nation-and European-wide.

Please fill out this form if you are attending.